Efficacy and Tolerability of Various Antimicrobial Regimens in the Treatment of Exacerbations of Chronic Bronchitis and Chronic Obstructive Pulmonary Disease in Outpatients

Open access

Efficacy and Tolerability of Various Antimicrobial Regimens in the Treatment of Exacerbations of Chronic Bronchitis and Chronic Obstructive Pulmonary Disease in Outpatients

Objective. To compare the efficacy and tolerability of different antibiotics empirically administered for exacerbations of chronic bronchitis and chronic obstructive pulmonary disease (COPD).

Methods. We performed an observational, non-randomized, open-label study including 226 outpatients with exacerbations of chronic bronchitis and mild or moderate COPD, 123 males and 103 females, aged 24 to 81. All patients were followed up for 30 days, with an intermediate visits at 5 and 10 days at which they were asked about the duration of symptoms (increased expectoration, increased dyspnea and/or presence of purulent sputum) and the side-effects of the drug. Five antibiotic regimens were evaluated: amoxicillin/clavulanic acid 875 mg/125 mg twice daily for 10 days, cefuroxime 250 mg twice daily for 10 days, cefixime 400 mg once daily for 10 days, clarithromycin 500 mg twice daily for 10 days, and ciprofloxacin 500 mg twice daily for 10 days.

Results. The clinical success rate, defined as a complete resolution or a return of the symptoms to the baseline severity, in the groups receiving amoxicillin/clavulanic acid, cefuroxime, cefixime, clarithromycin, and ciprofloxacin was 68.9%, 75.0%, 73.5%, 72.7%, and 77.1%, respectively. The mean time to relief of symptoms varied from 6.8 days with amoxicillin/clavulanic acid to 6.1 days with cefuroxime. Relapse within the first month was registered in the group receiving clarithromycin and ciprofloxacin (3.1% and 2.6%, respectively). The prevalence of the adverse events varied from 10.4% with ciprofloxacin, following by 8.9% for amoxicillin/clavulanic acid, 7.5% for cefixime, 6.8% with clarithromycin to 6.1% with cefuroxime.

Conclusion. Our findings suggest high efficacy and safety of all studied regimens in the treatment of exacerbations of chronic bronchitis and COPD.

If the inline PDF is not rendering correctly, you can download the PDF file here.

  • European Lung White Book. European Respiratory Society Journals & European Lung Foundation Lausanne 2003; p.34-40.

  • Pelkonen M Notkola I-L Nissinen A et al. Thirty-Year Cumulative Incidence of Chronic Bronchitis and COPD in Relation to 30-Year Pulmonary Function and 40-Year Mortality. Chest. 2006;130:1129-1137. doi:10.1378/chest.130.4.1129PMID:17035447

  • Bhowmik A Seemungal TA Sapsford RJ et al. Relation of sputum inflammatory markers to symptoms and lung function changes in COPD exacerbations. Thorax. 2000;55:114-120. doi:10.1136/thorax.55.2.114PMID:10639527PMCID:1745686

  • Miravittles M Niederman M. Lectures in Respiratory Tract Infections: Acute Exacerbations of Chronic Bronchitis. London: Science Press Ltd; 2004 p.7-8.

  • Ball P Chodosh S Grossman R et al. Causes epidemiology and treatment of bronchial infections. Infect Med. 2000;17:186-198.

  • Miravitlles M. Epidemiology of chronic obstructive pulmonary disease exacerbations. Clin Pulm Med. 2002;9:191-197. doi:10.1097/00045413-200207000-00001

  • Ball P. Epidemiology and treatment of chronic bronchitis and its exacerbations. Chest. 1995;108:43S-52S. doi:10.1378/chest.108.2_Supplement.43SPMID:7634925

  • Anthonisen NR Menfreda J Warren CP et al. Antibiotic therapy in exacerbations of chronic obstructive pulmonary disease. Ann Intern Med. 1987;106 (2):196-204. PMID:3492164

  • Stockley RA O'Brien C Pye A et al. Relationship of sputum color to nature and outpatient management of acute exacerbations of COPD. Chest. 2000;117:1638-1645. doi:10.1378/chest.117.6.1638PMID:10858396

  • Miravittles M Mayordomo C Artes T et al. Treatment of chronic obstructive pulmonary disease and its exacerbations in general practice: EOLO Group. Estudio Observacional de la Limitacion Obstructiva al Flujo Aereo. Respir Med. 1999;93(3):173-179. PMID:10464874

  • Global Initiative for Chronic Obstructive Lung Disease. Workshop report global strategy for diagnosis management and prevention of COPD: 2008 Update. Available at: http://www.goldcopd.org/

  • Miravittles M Llor C Naberan K et al. Effect of various antimicrobial regimens on the clinical course of exacerbations of chronic bronchitis and chronic obstructive pulmonary disease in primary care. Clin Drug Invest. 2004;24(2):63-72. doi:10.2165/00044011-200424020-00001

  • Medical Research Council. Definition and classification of chronic bronchitis for clinical and epidemiological purposes. A report to the Medical research Council by their committee on the Aetiology of Chronic Bronchitis. Lancet. 1965;i: 775-779. PMID:4165081

  • Andersson F Borg S Jansson S-A et al. The costs of exacerbations in chronic obstructive pulmonary disease (COPD). Respir Med. 2002;96:700-708. doi:10.1053/rmed.2002.1334PMID:12243316

  • Celli BR Barnes PJ. Exacerbations of chronic obstructive pulmonary disease. Eur Respir J. 2007;29:1224-1238. doi:10.1183/09031936.00109906PMID:17540785

  • Balter MS La Forge J Low D et al. Canadian guidelines for the management of acute exacerbations of chronic bronchitis. Can Respir J. 2003;10 Suppl B:3B-32B. PMID:12944998

  • BTS guidelines for the management of chronic obstructive pulmonary disease. The COPD Guidelines Group of the standards of Care Committee of the BTS. Thorax. 1997;52 Suppl 5:S1-S8. PMID:9474238

  • Snow V Lascher S Mottur-Pilson C. Evidence base for management of acute exacerbations of chronic obstructive pulmonary disease. Ann Intern Med. 2001;134(7):595-599. PMID:11281744

  • Gompertz S O'Brien C Bayley DL et al. Changes in bronchial inflammation during acute exacerbations of chronic bronchitis. Eur Respir J. 2001;17:1112-1119. doi:10.1183/09031936.01.99114901PMID:11491152

  • Minov J Cvetanov V Karadzinska-Bislimovska J et al. Epidemiological characteristics of bronchial asthma in R. Macedonia. Mak Med Pregled. 2003;56:156.

  • Perez-Trallero E Fernandez C Garcia-Rey C et al. Antimicrobial susceptibilities of 1684 Streptococcus pneumoniae and 2039 Streptococcus pyogenes isolates and their ecological relationships: results of a 1-year (1998-1999) multicenter surveillance study in Spain; Spanish Surveillance Group for Respiratory Pathogens. Antimicrob Agents Chemoter. 2001;45:3334-3340. doi:10.1128/AAC.45.12.3334-3340.2001PMID:11709305PMCID:90834

  • Doern GV Pfaller MA Kugler K et al. Prevalence of the antimicrobial resistance among respiratory tract isolates of in North America: 1997 results from the SENTRY Antimicrobial Surveillance Program. Clin Inf Dis. 1998;27:764-770. doi:10.1086/514953PMID:9798031

  • Sethi S Evans N Grant BJ et al. New strains of bacteria and exacerbations of chronic obstructive pulmonary disease. N Engl J Med. 2002;347:465-471. doi:10.1056/NEJMoa012561PMID:12181400

  • Garcia JA Baquero F Garcia J et al. Antimicrobial susceptibility of 1422 Haemophilus influenzae isolates from respiratory tract infections in Spain: results of a 1-year (1996-1997) multicenter surveillance study in Spain; Spanish Surveillance Group for Respiratory Pathogens. Infection. 1999;27:265-267. doi:10.1007/s150100050026PMID:10885840

  • Blondeau JM Tillotson GS. Antimicrobial susceptibility patterns of respiratory pathogens - a global perspective. Semin Respir Infect. 2000;15(3):195-207. PMID:11052420

  • Wilson R Allegra L Huchon G et al. Short-term and long-term outcomes of moxifloxacin compared to standard antibiotic therapy for the treatment of acute exacerbations of chronic bronchitis. Chest. 2004;125:953-964. doi:10.1378/chest.125.3.953PMID:15006954

  • Miravittles M Zalacain R Murio C et al. Speed of recovery from acute exacerbations of chronic obstructive pulmonary disease after treatment with antimicrobials: a results of a two-years study. IMPAC Study Group. Clin Drug Invest. 2003;23:439-450. doi:10.2165/00044011-200323070-00003PMID:17535055

  • Perry CM Brogden RN. Cefuroxime Axetil. A review of its antibacterial activity pharmacokinetic properties and therapeutic efficacy. Drugs. 1996;52(1):125-156. doi:10.2165/00003495-199652010-00009PMID:8799689

  • Destache CJ Dewan N O'Donohue WJ et al. Clinical and economic considerations in the treatment of acute exacerbations of chronic bronchitis. J Antimicrob Chemoth. 1999;43:107-113. doi:10.1093/jac/43.suppl_1.107PMID:10225580

Search
Journal information
Impact Factor


CiteScore 2016: 0.16

SCImago Journal Rank (SJR) 2016: 0.136
Source Normalized Impact per Paper (SNIP) 2016: 0.141

Metrics
All Time Past Year Past 30 Days
Abstract Views 0 0 0
Full Text Views 83 36 4
PDF Downloads 32 14 0